Fig. 2.

Performance and clinical value of magnetic resonance imaging radiomic signatures

(a) Overall distribution of key radiomic features from T1+C, T2WI, and DWI-ADC sequences among patients with and without ALN metastasis in the training cohort (n = 392). (b) Performance of the ALN-tumor radiomic signature for predicting ALN metastasis in the training (n = 392), the prospective-retrospective validation (n = 45), and the external validation (n = 112) cohorts. (c) Performance of the multiomic signature for predicting ALN metastasis in the training (n = 381), the prospective-retrospective validation (n = 30), and the external validation (n = 81) cohorts. (d) Decision curve analysis for the ALN-tumor radiomic signature and the multiomic signature (n = 381). ALN=axillary lymph node. AUC=area under the receiver operating characteristics curve. T1+C=contrast-enhanced T1-weighted imaging. T2WI=T2-weighted imaging. DWI-ADC=diffusion-weighted imaging quantitatively measured the apparent diffusion coefficient.